Buy AOD-9604

AOD 9604 is a synthetic fragment of human growth hormone (amino acids 176-191) engineered to target lipolysis and body composition research without the anabolic or IGF-1-stimulating effects associated with full-length HGH. Weight management physicians, sports medicine clinicians, and compounding pharmacists evaluating metabolic peptide therapy protocols will find a full clinical guide, mechanism overview, stacking strategies, and dosing framework below. Maylips emphasizes high purity standards and supply reliability for licensed professionals researching AOD 9604 peptide therapy options.

AOD 9604 Peptide Benefits & Body Composition Results

AOD 9604 (Anti-Obesity Drug 9604) is an investigational, synthetic fragment of human growth hormone modeled after amino acids 176–191. It was engineered to isolate hGH’s lipolytic (fat-metabolizing) domain while removing the receptor-binding domains responsible for anabolic signaling and IGF-1 stimulation. Because it leaves the central GH axis untouched, research data show no meaningful disruption of glucose metabolism or elevation of systemic IGF-1 [3].

However, clinicians must carefully separate its molecular design from its actual human trial performance:

• Underwhelming Clinical Efficacy: While animal models suggested early promise for fat oxidation and inhibition of new fat cell formation [1][2], human clinical results were ultimately disappointing. AOD 9604 underwent multiple Phase II trials involving more than 900 participants, establishing a resilient safety record but failing to meet primary fat-loss endpoints [3]. Human weight loss relative to placebo was a clinically negligible ~1.8 kg over 12 weeks, leading to the permanent halt of all commercial development in 2007 [3].
• Investigational Status Only: Current medical guidance advises against prescribing AOD 9604 for obesity. It should be framed strictly as an investigational compound for metabolic research rather than an established clinical weight-loss therapy. Furthermore, all injectable results are extrapolated entirely from practitioner reports and preclinical observations rather than from validated human trials.
• Preliminary Joint Research: Some in vitro and animal studies have examined whether the peptide affects cartilage repair pathways. However, this evidence remains strictly preliminary and is completely insufficient for clinical or musculoskeletal conclusions.

Critical Regulatory Boundaries

The FDA granted AOD 9604 GRAS (Generally Recognized As Safe) status in 2014 strictly for use as a food ingredient. This designation does not apply to injectable or pharmaceutical preparations, nor does it imply formal drug approval or safety clearance for research peptide use.

How AOD 9604 Works: HGH Fragment Mechanism of Action

The mechanism behind AOD 9604 differs significantly from traditional growth hormone therapies and GH secretagogues. Rather than stimulating systemic HGH production, the peptide is researched for direct effects on adipocyte signaling and lipolysis-related pathways.

• Fragment of Human Growth Hormone: AOD 9604 consists of amino acids 176-191 from human growth hormone. This fragment isolates the lipolytic region of HGH while removing the receptor-binding domains associated with anabolic signaling and IGF-1 stimulation, making it a distinct research tool from GH secretagogues.
• Lipolysis and Beta-3 Adrenergic Receptor Expression: Research in murine models has shown that AOD 9604 upregulates beta-3 adrenergic receptor expression on adipocytes rather than directly binding to the receptor [2]. This increase in receptor expression amplifies adipocyte sensitivity to catecholamine-driven lipolysis, triggering hormone-sensitive lipase activity and mobilizing stored fat for oxidation. The distinction between receptor upregulation and direct receptor binding is mechanistically important and should be communicated accurately in protocol discussions.
• Inhibition of New Fat Cell Formation: Murine data from Ng et al. (2000) suggested that AOD 9604 may also inhibit lipogenesis and reduce the formation of new fat cells [1]. These findings remain preclinical and continue to inform discussions of body-composition-focused peptide protocols, though they have not been confirmed in controlled human trials.
• No IGF-1 Stimulation: Human trial data confirmed that AOD 9604 does not significantly stimulate IGF-1 production or activate the GH receptor pathway [3]. For clinicians concerned about IGF-1-related effects, this remains one of the peptide’s most important differentiators from traditional GH secretagogues.
• No Glucose Disruption: Published Phase 2 trial findings suggested no major anti-insulin or glucose-disrupting effects during oral administration studies [3]. This stable metabolic signature differentiates AOD 9604 mechanistically from full human growth hormone, though it does not establish clinical weight-loss efficacy.

AOD 9604 & HGH Levels: What Practitioners Need to Know

AOD 9604 is not a GH secretagogue. It does not stimulate pituitary hormone release, increase GH pulse amplitude, or elevate systemic IGF-1. It acts via peripheral lipolytic mechanisms rather than by activating the hypothalamic-pituitary axis, making it relevant to investigational protocols in which systemic GH stimulation is undesirable or contraindicated.

Current evidence also suggests no receptor desensitization or feedback suppression commonly discussed with long-term secretagogue use. Practitioners should also recognize what AOD 9604 lacks: available evidence does not support improvements in lean mass, connective tissue support, recovery capacity, or sleep quality associated with broader human growth hormone effects. Communicating this distinction clearly supports evidence-based protocol design and accurate patient education.

Because AOD 9604 leaves the GH axis largely untouched, some clinicians view it as mechanistically compatible with secretagogue-based approaches. Professionals evaluating research peptide documentation carefully when buying online from research-focused suppliers should prioritize purity verification and batch traceability as core quality indicators.

Stacking AOD 9604: Protocol Combinations

Some clinicians and researchers explore stacking AOD-9604 with growth hormone secretagogues or related metabolic peptides to develop complementary investigational protocols. These combinations are practitioner-reported and mechanistically driven; all remain extrapolated from preclinical data and observational experience with no controlled human trial validation.

• CJC-1295 with DAC: Extends endogenous GH pulsatility through GHRH receptor stimulation, while AOD 9604 contributes direct lipolytic activity without substantially increasing GH-axis burden. The mechanisms are complementary rather than redundant, and this combination is among the most commonly discussed in practitioner-reported body composition protocols.
• Ipamorelin: Acts as a selective GHS-R agonist associated with pulsatile GH stimulation and relatively low elevations in cortisol or prolactin. Some clinicians combine it with AOD 9604 to pair targeted fat oxidation with conservative secretagogue support, though no controlled human trial data currently support this combination.
• Sermorelin: Stimulates physiological GH pulsatility through short-acting GHRH receptor activity. AOD 9604 is viewed as adding a peripheral lipolytic component without directly affecting pituitary signaling. As with all stacking approaches involving AOD 9604, this combination should be framed as investigational throughout any research or patient discussion.

AOD 9604 Peptide Dosage Chart & Administration

Published human studies evaluating AOD 9604 primarily used oral doses ranging from 1-5 mg daily. Injectable approaches remain practitioner-reported and extrapolated from preclinical research. For professionals researching where to buy AOD 9604 online, the dosing framework below reflects practitioner-reported references only; no injectable protocol has been validated in controlled human trials.

Practitioner-reported Subcutaneous Dosage

• Dose: 250-500 mcg daily
• Timing: fasted state, morning or pre-exercise
• Cycle length: 8-16 weeks commonly cited; no controlled long-term human safety data exist beyond Phase 2b oral findings

Reconstitution and Storage

• Reconstitute with bacteriostatic water
• Store at 2-8°C after reconstitution and protect from light
• Lyophilized powder is generally stable at room temperature during short-term transport
• Discard reconstituted solution per supplier or compounding pharmacy guidelines

Professionals seeking to buy AOD 9604 wholesale should check for wholesale buying options that include batch-specific purity testing and analytical verification documentation as standard procurement requirements.

AOD 9604 Peptide Side Effects, Safety & Legal Status

AOD 9604 demonstrated a strong safety profile across more than 900 participants in Phase II human trials, with no serious adverse events reported and generally mild, well-tolerated side effects [3]. Injection site redness and mild swelling are the most commonly reported concerns with subcutaneous administration. Current evidence does not indicate documented hypoglycemia, IGF-1-related complications, or significant joint changes in controlled studies. Long-term injectable safety data are lacking; clinicians should clearly communicate this limitation.

Current Regulatory Status

• United States: AOD 9604 is not FDA-approved for any therapeutic indication. The 2014 GRAS designation applies exclusively to food ingredient use and does not cover injectable or research peptide applications [4]. The FDA has classified AOD 9604 as a bulk drug substance with significant potential safety risks, citing concerns about immunogenicity and peptide-related impurities, and has restricted compounding pharmacies from dispensing it [4]. It was removed from the FDA 503A bulk drug substances compounding list in 2023 and is classified as a research compound only.
• Australia: Schedule 4, prescription-only under the Therapeutic Goods Administration. Verify current TGA status locally.
• WADA: AOD 9604 and hGH 176-191 are explicitly named on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [5]. Competitive athletes are prohibited from using this compound and must be clearly advised of this restriction before any discussion of the protocol.

AOD 9604 vs Tesamorelin, Sermorelin & CJC-1295

AOD 9604 is often compared with other metabolic and growth hormone-related peptides because of its unique non-secretagogue mechanism. These comparisons help practitioners distinguish differences in IGF-1 activity, GH-axis involvement, regulatory standing, and body composition outcomes when evaluating peptide therapy strategies.

Tesamorelin

AOD 9604 is an HGH fragment that targets direct lipolysis without IGF-1 stimulation or GH-axis involvement, while Tesamorelin is a GHRH analogue that stimulates pituitary GH release and elevates IGF-1. Tesamorelin holds FDA approval for HIV-associated lipodystrophy and carries the strongest regulatory standing in this category. Practitioners may consider AOD 9604 in investigational protocols where IGF-1 elevation is a concern, recognizing that AOD 9604 has no regulatory approval and a narrower, largely preclinical record of efficacy.

Sermorelin

Sermorelin promotes pulsatile endogenous GH release via central GHRH signaling, producing systemic GH effects, including potential support for lean mass and recovery. AOD 9604 targets only peripheral fat metabolism without affecting the GH axis, making it relevant to investigational protocols in which isolated lipolytic activity is the objective and systemic GH effects are not required. Some clinicians view these compounds as complementary rather than competing, using Sermorelin for physiological GH pulsatility and AOD 9604 for additive lipolytic activity.

CJC-1295

CJC-1295 with DAC produces prolonged GH elevation and broader body composition effects, including support for lean mass, while AOD 9604 produces no systemic GH elevation and focuses solely on direct lipolytic activity. Practitioners prioritizing targeted investigational research on fat metabolism without engaging the GH axis may evaluate AOD 9604; those seeking lean mass support or sustained GH activity alongside fat loss may evaluate CJC-1295 instead. The two compounds belong to different mechanistic categories and can be considered for complementary stacking rather than direct substitution.

Where to Source or Buy AOD 9604 Peptide: Guidance for Qualified Professionals

Because AOD 9604 is a research compound with no FDA-approved protocol and restricted compounding status, sourcing standards are particularly important for research consistency. This information is relevant to licensed and qualified professionals only.

When evaluating suppliers, professionals should confirm:

• Batch-specific certificates of analysis (COA)
• LOT number traceability
• Verifiable purity documentation and GMP-aligned manufacturing standards
• Post-reconstitution stability data and documented storage guidance

For institutions managing higher-volume procurement, professionals should also check for wholesale buying options that support supply continuity and documented quality standards across multiple orders.

Practitioners seeking guidance on where to buy AOD 9604 through verified research-grade suppliers, or with questions about documentation requirements and how to order AOD 9604 for research use, may contact the Maylips support team for sourcing direction and documentation support.

FAQs

1. What is AOD 9604 peptide, and how does it differ from HGH?

AOD 9604 is a synthetic fragment of human growth hormone (amino acids 176-191) that retains only the lipolytic domain and does not produce the anabolic, IGF-1-stimulating, or insulin-resistance effects of full-length HGH. The 2014 GRAS designation applies only to its use as a food ingredient and does not constitute drug approval or safety clearance for injectable research use [4].

2. What are the AOD 9604 peptide benefits?

Research in preclinical models suggests that AOD 9604 may support lipolysis by upregulating beta-3 adrenergic receptor expression and inhibiting new fat cell formation, with human trial data confirming no IGF-1 elevation or glucose disruption [2, 3]. The Phase IIb trial did not meet its primary fat-loss endpoint, and all benefit claims must be understood within the context of the evidence tier from which they derive.

3. What is the AOD 9604 peptide dosage?

Practitioner-reported injectable protocols commonly recommend subcutaneous doses of 250-500 mcg daily in a fasted state, whereas published human studies have evaluated oral doses between 1 and 5 mg daily. All AOD 9604 peptide dosing should be framed as research-based extrapolation rather than as a clinically validated recommendation; cycle lengths of 8-16 weeks are commonly cited.

4. What are the AOD 9604 peptide side effects?

AOD 9604 demonstrated a strong safety profile in more than 900 participants in Phase II human trials, with no serious adverse events; injection-site redness and swelling are the most commonly reported concerns with subcutaneous use [3]. Long-term injectable safety data remain unavailable. AOD 9604 is explicitly prohibited by WADA under S2; competitive athletes must be advised they cannot use this compound [5].

5. Can AOD 9604 be stacked with other peptides?

Practitioner-reported stacking AOD-9604 protocols frequently involve CJC-1295, Ipamorelin, and Sermorelin, as AOD 9604 leaves the GH axis untouched and is viewed as mechanistically compatible with secretagogue-based investigational approaches. No controlled human studies currently validate these combinations, and all stacking approaches should be framed as practitioner-reported and investigational throughout.

Sources

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem.v3i1-2.157
4. S. Food and Drug Administration. Certain bulk drug substances used in compounding may present significant safety risks. Updated April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. World Anti-Doping Agency. WADA statement on substance AOD-9604. WADA-AMA.org. https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604
6. Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. doi:10.2174/157340313805076322

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.